GeNeuro Announces Approval of all Resolutions Proposed at 2022 Annual General Meeting

Geneva, Switzerland, June 2, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General […]

GeNeuro announces successful €7.7 million private placement

Geneva, Switzerland,  May 12, 2022 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today announced the successful completion of a €7.7 million capital increase with cancellation of […]

GeNeuro is granted authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post COVID syndromes

Geneva, Switzerland, May 11, 2022– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announces today it has received the authorization by the Swiss Health Authority (Swissmedic) to […]

GeNeuro publishes its 2021 Universal Registration Document

Geneva, Switzerland, April 27, 2022 – 6:00 pm CEST GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), publishes its 2021 Universal Registration Document, in English, which has been filed on April 27, […]

GeNeuro: financial information for the first quarter 2022

Geneva, Switzerland, April 15, 2022 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 first quarter cash position. https://geneuro.ch/data/news/GeNeuro-PR-Q1-2022-EN.pdf

GeNeuro and FondaMental Foundation announce the first results of the collaboration for the development of diagnostic and therapeutic options for patients with post-COVID neuropsychiatric syndromes

Geneva, Switzerland, April 13, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), and the FondaMental Foundation, a scientific cooperation foundation serving patients with mental […]

GeNeuro Reports 2021 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 4, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), reports today its full-year results for the year ended December 31, 2021 and provided […]

ProTEct-MS Phase 2 trial confirms safety of higher doses of temelimab and synergistic potential to address neurodegeneration on top of anti-inflammatory treatment in multiple sclerosis

Geneva, Switzerland, March 21, 2022 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis, today announced that the top-line results of the ProTEct-MS study confirm the excellent safety profile and tolerability of higher doses […]

INTERVIEW : Jesús Martin-Garcia, Président Directeur Général de GeNeuro, revient sur les développements de GeNeuro dans la sclérose en plaques et sur le lien avec le virus d’Epstein-Barr

Genève, Suisse, le 10 mars 2022 – GeNeuro (Euronext Paris : CH0308403085 – GNRO), une société biopharmaceutique développant de nouveaux traitements pour les maladies neurodégénératives et auto-immunes, telles que la sclérose en plaques (SEP), la sclérose latérale amyotrophique (SLA) et les conséquences neuropsychiatriques sévères de COVID-19 (post-COVID), annonce aujourd’hui sa situation de trésorerie au 31 décembre 2021 […]

GeNeuro announces the completion of its ProTEct-MS study and confirms the March timeline for top-line results, provides a Business Update and Cash Position as of December 31, 2021

Geneva, Switzerland, January 27, 2022 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position […]